Interestingly, the phosphodiesterase IV (PDE4D) inhibitor roflumilast has been reported to ameliorate the symptoms of T2DM and insulin resistance by potentiating cAMP signaling, possibly influencing insulin secretion [83]. This evidence concerns the gene INS and type 2 diabetes mellitus.